Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NIA24 is a topical cosmeceutical skincare line developed by Niadyne Pharma (Niadyne Inc.) based on over 25 years of biomedical research. The core technology is Pro-Niacin (myristyl nicotinate), a proprietary, lipophilic derivative of niacin (vitamin B3) designed to penetrate the skin barrier and deliver nicotinic acid to the deeper layers of the skin via a micronutrient delivery system. Once absorbed, Pro-Niacin converts to nicotinamide adenine dinucleotide (NAD), which stimulates DNA repair by activating PARP (poly-ADP-ribose polymerase) and enhances energy metabolism within skin cells. The technology also targets the niacin receptor (HCAR2/GPR109A) to strengthen the skin's natural barrier and improve overall skin texture. NIA24 was marketed for consumer indications including photodamage, hyperpigmentation, fine lines, and wrinkles, though the brand has reportedly been discontinued.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NIA24.